Literature DB >> 27065313

Longitudinal Assessment of Small Fiber Neuropathy: Evidence of a Non-Length-Dependent Distal Axonopathy.

Mohammad A Khoshnoodi1, Shaun Truelove2, Ahmet Burakgazi3, Ahmet Hoke1, Andrew L Mammen4, Michael Polydefkis1.   

Abstract

IMPORTANCE: Few data are available on the natural history of small fiber neuropathy (SNF). Peripheral neuropathy typically follows a length-dependent pattern, leading us to hypothesize that patients with SFN would lose intraepidermal nerve fibers at the distal leg more quickly than at more proximal thigh sites.
OBJECTIVE: To compare the longitudinal rate and pattern of intraepidermal nerve fiber density (IENFD) change in idiopathic SFN (iSFN), impaired glucose tolerance-associated SFN (IGT-SFN), and diabetes mellitus-associated SFN (DM-SFN). DESIGN, SETTING, AND PARTICIPANTS: In this longitudinal, case-control study, patients diagnosed as having SFN from January 1, 2002, through December 31, 2010, and age- and sex-matched controls underwent additional evaluation at tertiary outpatient neurology clinics. Participants and healthy controls were evaluated twice separated by at least 2 years. Participants underwent standardized examinations, nerve conduction, and skin biopsy at 3 sites along the leg. A linear mixed-effects model was used to compare rates of IENFD decrease between cause and biopsy site. MAIN OUTCOMES AND MEASURES: We compared the rate of IENFD loss over time in subjects with iSFN, IGT-SFN and DM-SFN as well as the spatiotemporal pattern of IENF loss at different rostal-caudal sites along the leg.
RESULTS: Fifty-two participants (25 with iSFN, 13 with IGT-SFN, and 14 with DM-SFN) and 10 healthy controls were evaluated. Mean (SD) ages were 50.9 (12.9), 63.1 (10.4), and 61.6 (11.6) years for the iSFN, IGT-SFN, and DM-SFN groups, respectively. There were 12, 7, and 8 female patients and 13, 6, and 6 male patients in the iSFN, IGT-SFN, and DM-SFN groups, respectively. The mean follow-up time was 24.2, 26.7, and 38.8 months for those with iSFN, IGT-SFN, and DM-SFN, respectively, and 32 months for healthy controls. At baseline, mean (SE) for distal leg IENFD (6.48 [1.06]) was lower than distal thigh (13.32 [1.08]) and proximal thigh IENFD (19.98 [1.07]) (P = .001). In addition, IENFD was significantly lower in patients with DM-SFN and IGT-SFN compared with iSFN at all biopsy sites (P = .001). All 3 neuropathy groups had significant IENFD decrease at follow-up at all 3 sites (P = .002), whereas there was no change in the control group. The mean yearly rates of IENFD change over time at the distal leg, distal thigh, and proximal thigh irrespective of cause are -1.42, -1.59, and -2.8 fibers per millimeter, respectively. The mean slopes of IENFD change over time by cause regardless of biopsy site are -0.179, -0.164, and -0.198 for iSFN, IGT-SFN, and DM-SFN, respectively. No difference was found between SFN groups in the rate of decrease. The rate of IENFD decrease was similar at all 3 biopsy sites. CONCLUSIONS AND RELEVANCE: Similar rates of IENFD decrease irrespective of cause were observed. Epidermal nerve fibers were lost at similar rates in proximal and distal sites, suggesting that SFN is a non-length-dependent terminal axonopathy.

Entities:  

Mesh:

Year:  2016        PMID: 27065313     DOI: 10.1001/jamaneurol.2016.0057

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  19 in total

Review 1.  Current Diagnosis and Treatment of Painful Small Fiber Neuropathy.

Authors:  Khosro Farhad
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

Review 2.  Diabetes Distal Peripheral Neuropathy: Subtypes and Diagnostic and Screening Technologies.

Authors:  Kelley Newlin Lew; Tracey Arnold; Catherine Cantelmo; Francky Jacque; Hugo Posada-Quintero; Pooja Luthra; Ki H Chon
Journal:  J Diabetes Sci Technol       Date:  2022-01-07

Review 3.  Small Fiber Neuropathy.

Authors:  N Strand; C Wie; J Peck; M Maita; N Singh; J Dumbroff; V Tieppo Francio; M Murphy; K Chang; D M Dickerson; J Maloney
Journal:  Curr Pain Headache Rep       Date:  2022-04-06

4.  Dietary weight loss in people with severe obesity stabilizes neuropathy and improves symptomatology.

Authors:  Brian C Callaghan; Evan L Reynolds; Mousumi Banerjee; Gulcin Akinci; Ericka Chant; Emily Villegas-Umana; Amy E Rothberg; Charles F Burant; Eva L Feldman
Journal:  Obesity (Silver Spring)       Date:  2021-11-07       Impact factor: 5.002

5.  Small Fiber Neuropathy Incidence, Prevalence, Longitudinal Impairments, and Disability.

Authors:  Stephen A Johnson; Kamal Shouman; Shahar Shelly; Paola Sandroni; Sarah E Berini; P James B Dyck; Ernest Matthew Hoffman; Jay Mandrekar; Zhiyv Niu; Christopher J Lamb; Phillip A Low; Wolfgang Singer; Michelle L Mauermann; John Mills; Divyanshu Dubey; Nathan P Staff; Christopher J Klein
Journal:  Neurology       Date:  2021-10-27       Impact factor: 9.910

6.  The First Electrophysiological Abnormality in New-onset DM: Autonomic Tests.

Authors:  Zülfikar Memiş; Nihat Çevik; Hürtan Acar; Sefer Günaydin; Özlem Çokar
Journal:  Noro Psikiyatr Ars       Date:  2022-08-16       Impact factor: 1.066

7.  High-resolution ultrasound of peripheral nerves in late-onset hereditary transthyretin amyloidosis with polyneuropathy: similarities and differences with CIDP.

Authors:  Luca Leonardi; Giuseppe Di Pietro; Antonella Di Pasquale; Fiammetta Vanoli; Laura Fionda; Matteo Garibaldi; Eleonora Galosi; Girolamo Alfieri; Antonio Lauletta; Stefania Morino; Marco Salvetti; Andrea Truini; Giovanni Antonini
Journal:  Neurol Sci       Date:  2021-11-21       Impact factor: 3.830

8.  Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery.

Authors:  Krystyna M Wozniak; James J Vornov; Ying Wu; Ying Liu; Valentina A Carozzi; Virginia Rodriguez-Menendez; Elisa Ballarini; Paola Alberti; Eleonora Pozzi; Sara Semperboni; Brett M Cook; Bruce A Littlefield; Kenichi Nomoto; Krista Condon; Sean Eckley; Christopher DesJardins; Leslie Wilson; Mary A Jordan; Stuart C Feinstein; Guido Cavaletti; Michael Polydefkis; Barbara S Slusher
Journal:  Cancer Res       Date:  2017-11-30       Impact factor: 12.701

Review 9.  The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.

Authors:  Shannon M Smith; Robert H Dworkin; Dennis C Turk; Ralf Baron; Michael Polydefkis; Irene Tracey; David Borsook; Robert R Edwards; Richard E Harris; Tor D Wager; Lars Arendt-Nielsen; Laurie B Burke; Daniel B Carr; Amy Chappell; John T Farrar; Roy Freeman; Ian Gilron; Veeraindar Goli; Juergen Haeussler; Troels Jensen; Nathaniel P Katz; Jeffrey Kent; Ernest A Kopecky; David A Lee; William Maixner; John D Markman; Justin C McArthur; Michael P McDermott; Lav Parvathenani; Srinivasa N Raja; Bob A Rappaport; Andrew S C Rice; Michael C Rowbotham; Jeffrey K Tobias; Ajay D Wasan; James Witter
Journal:  J Pain       Date:  2017-02-27       Impact factor: 5.820

10.  The relationship of one-leg standing time with peripheral nerve function and clinical neuropathy in patients with type 2 diabetes.

Authors:  Kazuhiro Sugimoto; Takehiko Hoshino; Akira Tamura; Toshiro Yamazaki; Susumu Suzuki; Takuro Shimbo
Journal:  Diabetol Int       Date:  2018-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.